Latest News
Keep up to date with the latest news and announcements from Theragnostics
Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals
September 22, 2021Theragnostics Strengthens Board of Directors with Key Appointments
August 4, 2021Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging
February 17, 2021Developing radionuclide PARP inhibitors – MedNous Article
November 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference
November 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics
September 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research Programme
June 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership Recognition
May 7, 2020Theragnostics attending PSMA Masterclass – London
March 5, 2020News Archive
Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals
September 22, 2021Theragnostics Strengthens Board of Directors with Key Appointments
August 4, 2021Theragnostics Announces a research collaboration with Essen University Hospital to study THG-008 for Oncology PET Imaging
February 17, 2021Developing radionuclide PARP inhibitors – MedNous Article
November 19, 2020Theragnostics Holding 1-2-1 Meetings at Jefferies 2020 Virtual London Healthcare Conference
November 10, 2020Summit Biomedical Imaging Signs Agreement with Theragnostics Enabling the Development of Novel Fluorescence-Based Cancer Diagnostics
September 9, 2020Theragnostics Collaborate on £6 million MITHRAS Research Programme
June 2, 2020Dr Greg Mullen, Theragnostics CEO Gains Leadership Recognition
May 7, 2020News Archive